Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an announcement.
Alligator Bioscience’s board has executed a directed issue of 18,585,000 units to guarantors of its recent rights issue, with each unit consisting of two ordinary shares and one warrant, at a subscription price of SEK 0.40 per unit (SEK 0.20 per share), matching the rights issue terms. Eleven guarantors opted to take their guarantee compensation in newly issued units worth approximately SEK 7.4 million, while the remaining guarantors will receive around SEK 3.8 million in cash, and the board has also approved a directed issue of 28,132,473 warrants to Fenja Capital, collectively strengthening the company’s capital structure and aligning key investors through equity-linked instruments, albeit at the cost of further dilution for existing shareholders.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.32 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Swedish biotechnology company based in Lund, focused on developing innovative immuno-oncology therapies. The company is active in early- and mid-stage drug development, targeting cancer treatments and collaborating with specialized life science investors to secure financing for its clinical pipeline.
Average Trading Volume: 4,527,132
Technical Sentiment Signal: Sell
Current Market Cap: SEK165.8M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.